650 related articles for article (PubMed ID: 10628899)
1. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology.
Fanni D; Ambu R; Gerosa C; Nemolato S; Castagnola M; Van Eyken P; Faa G; Fanos V
Int J Immunopathol Pharmacol; 2014; 27(1):5-13. PubMed ID: 24674673
[TBL] [Abstract][Full Text] [Related]
4. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
[TBL] [Abstract][Full Text] [Related]
5. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
6. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
8. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman S
Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
[TBL] [Abstract][Full Text] [Related]
9. Developmental expression of the major human hepatic CYP3A enzymes.
Stevens JC; Hines RN; Gu C; Koukouritaki SB; Manro JR; Tandler PJ; Zaya MJ
J Pharmacol Exp Ther; 2003 Nov; 307(2):573-82. PubMed ID: 12975492
[TBL] [Abstract][Full Text] [Related]
10. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
11. Drugs as CYP3A probes, inducers, and inhibitors.
Liu YT; Hao HP; Liu CX; Wang GJ; Xie HG
Drug Metab Rev; 2007; 39(4):699-721. PubMed ID: 18058330
[TBL] [Abstract][Full Text] [Related]
12.
Work HM; Kandel SE; Lampe JN
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38702193
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of CYP3A polymorphisms.
Wojnowski L; Kamdem LK
Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):171-82. PubMed ID: 16866606
[TBL] [Abstract][Full Text] [Related]
14. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age.
Fakhoury M; Litalien C; Medard Y; Cavé H; Ezzahir N; Peuchmaur M; Jacqz-Aigrain E
Drug Metab Dispos; 2005 Nov; 33(11):1603-7. PubMed ID: 16049125
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.
Stevens JC
Drug Discov Today; 2006 May; 11(9-10):440-5. PubMed ID: 16635807
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
19. Developmental expression of cytochrome P450 enzymes in human liver.
Hakkola J; Tanaka E; Pelkonen O
Pharmacol Toxicol; 1998 May; 82(5):209-17. PubMed ID: 9646325
[TBL] [Abstract][Full Text] [Related]
20. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Yamaori S; Yamazaki H; Suzuki A; Yamada A; Tani H; Kamidate T; Fujita Ki; Kamataki T
Biochem Pharmacol; 2003 Dec; 66(12):2333-40. PubMed ID: 14637191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
